Applying the Evidence in Acute Lymphoblastic Leukemia From Pediatric to Adult Case Scenarios

/ Print /
| ShareMore
/ Text Size +
12/16/21 12:00 pm EDT
Virtual Webinar
United States

The Medical Crossfire®: Applying the Evidence in Acute Lymphoblastic Leukemia From Pediatric to Adult Case Scenarios is not to be missed!

The American Cancer Society estimates that 5690 people will receive a diagnosis of acute lymphoblastic leukemia (ALL) in 2021 and that 1580 will die of this heterogeneous hematologic malignancy. In recent years, increased understanding of the disease pathophysiology has led to identification of new cytogenetic and molecular abnormalities and the subsequent development of novel targeted agents for the treatment of ALL. The addition of tyrosine kinase inhibitors (TKIs), monoclonal antibodies, novel immune therapies, and chimeric antigen receptor [CAR] T cells to the treatment landscape has resulted in improved clinical outcomes. These developments have shifted clinical management from a one-size-fits-all approach to more individualized treatments based on immunophenotypic, cytogenetic, and molecular features.

The learning objectives of this program are:

  • Develop individualized treatment strategies for adults and pediatric patients with ALL based on cytogenetic and immunophenotype characteristics
  • Apply current and emerging data regarding the role of minimal residual disease assessment in determining prognosis and in treatment planning for adult and AYA patients with ALL 
  • Assess the efficacy and safety of current and emerging therapies, including monoclonal antibodies, antibody-drug conjugates, and CAR T-cell therapies in the management of this disorder
  • Discuss evidence-based recommendations in the context of the role of antibody therapy in newly diagnosed or relapsed/refractory ALL management, including in Ph-negative and Ph- positive disease, as a pretransplant strategy, or in patients with residual disease


Thursday, December 16, 2021
 12:00 PM – 2:00 PM EST
 Live, Interactive Webcast

Program Chair

Elias Jabbour, MD
Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX